FDA
-
-
-
-
-
-
-
Pfizer's BRAFTOVI shows improved survival in colorectal cancer trial
-
-
-
-
-
-
-
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
-
-
-
-
-
-
-
FDA intends to put most serious warning on COVID vaccines, CNN reports
-
-
-
-
-
-
-
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
-
-
-
-
-
-
-
FDA approves Keytruda and Padcev combo for bladder cancer treatment
-
-
-
-
-
-
-
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
-
-
-
-
-
-
-
Arvinas and Pfizer to out-license vepdegestrant commercialization rights
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

